Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Curdin Conrad

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
Predicting Psoriatic Arthritis in Psoriasis Patients - A Swiss Registry StudyMia-Louise Nielsen, Troels C Petersen, Lara Valeska Maul, et al.
Dermatology (Basel, Switzerland)|January 20, 2017
Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis RegistryPierre Jungo, Julia-Tatjana Maul, Vahid Djamei, et al.
Nature Communications|December 18, 2024
Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseasesTeofila Seremet, Jeremy Di Domizio, Antoine Girardin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 29, 2024
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case seriesNiccolò Gori, Elena Ippoliti, Silvia Mariel Ferrucci, et al.
Advances in Therapy|May 8, 2020
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA StudyUta Kiltz, Petros P Sfikakis, Karl Gaffney, et al.
Acta Dermato-Venereologica|February 7, 2025
Sex Disparities of Health-related Quality of Life in Moderate to Severe Psoriasis: A Real-world Analysis from the Swiss Psoriasis Registry (SDNTT)Ramtin Lichtenberger, Lara Valeska Maul, Ion Birkenmaier, et al.
Dermatology (Basel, Switzerland)|January 12, 2017
Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTTJulia-Tatjana Maul, Vahid Djamei, Antonios G A Kolios, et al.
The British Journal of Dermatology|April 28, 2022
Biomarkers of disease progression in people with psoriasis: a scoping reviewRavi Ramessur, Mark Corbett, David Marshall, et al.
The British Journal of Dermatology|May 24, 2022
Biomarkers of systemic treatment response in people with psoriasis: a scoping reviewMark Corbett, Ravi Ramessur, David Marshall, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2025
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysisFranz J Legat, Shawn G Kwatra, Adam Reich, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
Predicting Psoriatic Arthritis in Psoriasis Patients - A Swiss Registry StudyMia-Louise Nielsen, Troels C Petersen, Lara Valeska Maul, et al.
Dermatology (Basel, Switzerland)|January 20, 2017
Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis RegistryPierre Jungo, Julia-Tatjana Maul, Vahid Djamei, et al.
Nature Communications|December 18, 2024
Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseasesTeofila Seremet, Jeremy Di Domizio, Antoine Girardin, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 29, 2024
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case seriesNiccolò Gori, Elena Ippoliti, Silvia Mariel Ferrucci, et al.
Advances in Therapy|May 8, 2020
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA StudyUta Kiltz, Petros P Sfikakis, Karl Gaffney, et al.
Acta Dermato-Venereologica|February 7, 2025
Sex Disparities of Health-related Quality of Life in Moderate to Severe Psoriasis: A Real-world Analysis from the Swiss Psoriasis Registry (SDNTT)Ramtin Lichtenberger, Lara Valeska Maul, Ion Birkenmaier, et al.
Dermatology (Basel, Switzerland)|January 12, 2017
Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTTJulia-Tatjana Maul, Vahid Djamei, Antonios G A Kolios, et al.
The British Journal of Dermatology|April 28, 2022
Biomarkers of disease progression in people with psoriasis: a scoping reviewRavi Ramessur, Mark Corbett, David Marshall, et al.
The British Journal of Dermatology|May 24, 2022
Biomarkers of systemic treatment response in people with psoriasis: a scoping reviewMark Corbett, Ravi Ramessur, David Marshall, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2025
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysisFranz J Legat, Shawn G Kwatra, Adam Reich, et al.
Pageof 12